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Plasmodium falciparum HRP2 ELISA 
for analysis of dried blood spot samples  
in rural Zambia
Lauren E. Gibson1,2, Christine F. Markwalter1, Danielle W. Kimmel1, Lwiindi Mudenda1, Saidon Mbambara3, 
Philip E. Thuma3 and David W. Wright1* 
Abstract 
Background: Dried blood spots are commonly used for sample collection in clinical and non-clinical settings. This 
method is simple, and biomolecules in the samples remain stable for months at room temperature. In the field, blood 
samples for the study and diagnosis of malaria are often collected on dried blood spot cards, so development of a 
biomarker extraction and analysis method is needed.
Methods: A simple extraction procedure for the malarial biomarker Plasmodium falciparum histidine-rich protein 2 
(HRP2) from dried blood spots was optimized to achieve maximum extraction efficiency. This method was used to 
assess the stability of HRP2 in dried blood spots. Furthermore, 328 patient samples made available from rural Zambia 
were analysed for HRP2 using the developed method. These samples were collected at the initial administration of 
artemisinin-based combination therapy and at several points following treatment.
Results: An average extraction efficiency of 70% HRP2 with a low picomolar detection limit was achieved. In specific 
storage conditions HRP2 was found to be stable in dried blood spots for at least 6 months. Analysis of patient samples 
showed the method to have a sensitivity of 94% and a specificity of 89% when compared with microscopy, and 
trends in HRP2 clearance after treatment were observed.
Conclusions: The dried blood spot ELISA for HRP2 was found to be sensitive, specific and accurate. The method was 
effectively used to assess biomarker clearance characteristics in patient samples, which prove it to be ideal for gaining 
further insight into the disease and epidemiological applications.
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Background
Sample collection is a major challenge for disease diag-
nosis in non-clinical settings. In low-resource areas, the 
collection of venous blood is not always feasible, so blood 
samples are often collected via finger prick and stored 
on filter paper cards. These samples, called dried blood 
spots (DBS), result in increased biomolecule sample sta-
bility compared to liquid samples, as they can be stored 
in ambient conditions. Additionally, DBS samples have a 
low biohazard risk and thus can be easily shipped [1, 2]. 
These advantages have led to the commercial availabil-
ity of several types of DBS collection cards with differ-
ent features including easy labelling and incorporation of 
reagents for blood lysis or biomarker stability [3].
Dried blood spot samples have proven useful for 
the analysis of a variety of markers including proteins, 
nucleic acids, and drugs. Methods employing DBS 
require an extraction procedure followed by techniques 
such as ELISA or PCR to analyse the extracted samples 
[4]. For example, detection of hepatitis C, a measles spe-
cific antibody, and Streptococcus pneumoniae from DBS 
samples were shown to be reliable when validated against 
gold standards for detection [5–7]. Additionally, dried 
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blood spots are extensively used in newborn screening 
programmes which test for congenital disorders includ-
ing those that are metabolic, such as hyperthyroidism, 
and those that are genetic, such as cystic fibrosis [8–10].
Malaria, a parasitic disease transmitted through mos-
quitoes, caused 212 million infections in 2015. A major-
ity of these cases occurred in Africa, where access to 
clinical laboratories is limited [11]. Malaria is regu-
larly diagnosed with rapid diagnostic tests (RDTs) that 
detect Plasmodium falciparum histidine-rich protein 2 
(HRP2), a uniquely structured and highly stable protein 
biomarker [12]. In this work, a method for the extrac-
tion of HRP2 from dried blood spots was optimized. 
Various parameters were explored including extraction 
buffer, mixing method and extraction time. Addition-
ally, the percent recovery of HRP2 and the biomarker 
stability were studied. Following extraction, a previously 
developed HRP2 ELISA was used for biomarker quantifi-
cation [13]. This ELISA can detect low-level or asympto-
matic infections that may otherwise be undetectable, and 
its high-throughput nature is useful for epidemiological 
studies [14]. The coupling of the optimized extraction 
method with this ELISA allowed for detection of HRP2 
from DBS; a procedure that was then used to test patient 
samples in rural Zambia. This study allowed for determi-
nation of the method sensitivity, specificity and repro-
ducibility, as well as biomarker clearance characteristics.
Methods
Materials
Human Whole Blood (K3 EDTA) was purchased from 
Bioreclamation IVT (Catalog No. HMWBEDTA3). 
Plasmodium falciparum D6 parasite was cultured in 
house. Recombinant HRP2 protein (rc-HRP2) for tra-
ditional ELISA standard curve was purchased from 
Immunology Consultants Laboratory Inc. (Catalog No. 
AGPF-55). ELISA capture and detection antibodies 
were acquired from Abcam Inc. (Catalog Nos. ab9206 
and ab30384). Immulon 2HB ELISA plates (Cata-
log No. 14-245-61) and TMB One ELISA substrate 
(Catalog No. PR-G7431) were purchased from Fisher 
Scientific. 903 Protein Saver cards and Whatman 3 
filter paper, were purchased from GE Healthcare Life 
Sciences (Catalog Nos. 10534612 and 1003-055). Bio-
punches, 6  mm, were acquired from Ted Pella Inc. 
(Catalog No. 15111-60). All other reagents were pur-
chased from either Fisher Scientific or Sigma Aldrich. 
DBS extraction was performed with a Fisher Scien-
tific Analog Vortex Mixer (Catalog No. 02-215-365). 
Absorbance measurements were collected on a Biotek 
Synergy H4 microplate reader (Vanderbilt University) 
or Biotek ELx808 microplate reader (Macha Research 
Trust).
Plasmodium falciparum histidine‑rich protein 2 ELISA 
protocol
The HRP2 ELISA protocol has been previously reported 
[13]. Briefly, 1 µg/mL of anti-HRP2 IgM (ab9206) in PBS 
was immobilized for 1  h in an Immulon 96-well plate, 
which was then blocked with 5% BSA in PBST (1× PBS, 
0.1% Tween-20) for 2  h. Samples were then diluted in 
sample buffer (PBST, 0.1% BSA) and added to the plate 
for 2 h. Finally, horseradish peroxidase conjugated detec-
tion antibody (ab30384) was added at 0.5 µg/mL in PBST 
with 0.5% BSA for 1 h. Signal was visualized with TMB-
One, a commercially available 3,3′,5,5′-tetramethylbenzi-
dine (TMB) substrate and stopped with 2 M sulfuric acid 
after 10 min. Absorbance was read at 450 nm.
Dried blood spot extraction
DBS were prepared by spiking P. falciparum D6 parasite 
culture into whole blood and spotting 10 μL onto What-
man 903 Protein Saver cards (903 cards) or Whatman 3 
filter paper (W3). Extraction was performed on 6  mm 
spots. Two spots were extracted for each sample, in one, 
2-mL microcentrifuge tube with 300  µL PBST extrac-
tion buffer. The tubes were vortexed at maximum speed 
(3200  rpm) for 10  min. Afterwards, tubes were centri-
fuged to remove bubbles and spin down the DBS paper. 
The supernatant was then removed and analysed by 
ELISA.
Dried blood spot Plasmodium falciparum histidine‑rich 
protein 2 ELISA
The previously reported HRP2 ELISA [13] was per-
formed with the following modifications: (1) The stand-
ard curve was made from DBS standards to incorporate 
extraction conditions into the standard curve, (2) sam-
ples were directly added to the plate in the PBST extrac-
tion buffer instead of being diluted in sample buffer.
Percent recovery calculation
Percent recovery was determined by comparing ELISA 
signal from a blank (whole blood diluted 1:14 in PBST) 
and a positive control (whole blood spiked with parasite 
to 200 parasites/µL, diluted 1:14 in PBST) to ELISA sig-
nal from an extracted DBS sample. For example, percent 
recovery for a 200 parasites/µL DBS sample was calcu-
lated using the following equation:
Stability study
Dried blood spots were prepared on 903 cards and W3. 
The spots were stored in Ziploc bags containing desic-
cant at the following temperatures: room temperature 
(RT), 4, −20 and −80 °C. Samples were stored for various 
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lengths of time, extending up to 6 months, and analysed 
for percent recovery of HRP2.
Study setting
Patient samples were collected during a separate study 
carried out in the Nchelenge District of Zambia, an 
area where malaria transmission has been sustained 
at a high level despite interventions [15]. The original 
study was designed to determine parasite clearance rates 
after treatment with artemisinin-based combination 
therapy (ACT) in children under 5 years of age present-
ing with uncomplicated malaria to the local clinic. The 
anonymized samples were made available for the current 
study to determine if HRP2 clearance could be used as a 
proxy for parasite clearance rates.
Patient recruitment and ethics
Children who arrived at the clinic and tested positive for 
malaria according to SD Bioline HRP2 malaria RDTs were 
recruited for this study after the parent or guardian pro-
vided signed informed consent. The study and samples 
were collected under IRB approval TDRC/C4/09/2014 
as well as after approval was granted by the Zambian 
National Health Research Authority (MH/101/17/6).
Patient samples
Patient finger-prick blood samples were collected on 
903 cards between December 2014 and August 2015. 
DBS HRP2 ELISA analysis was done in July 2016. In 
the interim between collection and analysis, the DBS 
samples were stored at −20  °C. At the time of collec-
tion, finger-prick samples were analysed by thick smear 
microscopy to determine quantitative parasite levels by 
counting parasites per 200 white blood cells and then 
using an estimate of 8000  WBC/μL to obtain the para-
site count for that particular time point. This analysis was 
used as the gold standard in this study. After diagnosis 
by RDT and P. falciparum parasitaemia confirmation by 
a malaria smear, patients were enrolled and treated with 
artemether–lumefantrine (Coartem®). Thick blood film 
malaria smears and DBS samples were collected at 15 
time points: 0, 6, 12, 18, 24, 30, 36, 42, and 48 h and days 
3, 7, 14, 21, 28, and 35. In the current study, samples from 
time points 0, 6, 12 and 18 h as well as days 28 and/or 35 
were made available and analysed for 35 patients. Addi-
tionally, all 15 time points were studied for 10 patients.
Patient sample dried blood spot ELISA
Before analysis, patient samples were coded to ensure 
assays were performed blinded to microscopy results. 
To begin, one, 6-mm DBS spot was placed in a 2  mL 
microcentrifuge tube with 300  µL of PBST extraction 
buffer. After vortexing for 10 min, the supernatants were 
removed for analysis by HRP2 ELISA with two modifi-
cations: (1) the standard curve (0–20 parasites/µL) was 
made from D6 parasite culture spiked into 1:29 (v:v) 
whole blood in PBST to approximate DBS extract matrix, 
and (2) after extraction, the samples were diluted tenfold 
in PBST before addition to the plate.
Sample size calculation
Appropriate sample size is essential for validation of diag-
nostic tests. Buderer reported an equation for calculation 
of sample size to ensure that a planned study would have 
sufficient power [16, 17]. This number is dependent on 
estimated sensitivity or specificity, and equations for each 
are shown below. To ensure sufficient sample size, the 
larger of the two was chosen.
Variables are defined as: n  =  number of samples, 
Se =  sensitivity, Sp =  specificity, Z =  Z score (1.96 for 
this analysis), d = confidence interval, and Prev = preva-
lence of disease. For this study, we chose d = 0.1. For this 
analysis, the prevalence was approximated at 70% and 
the desired sensitivity and specificity were 90 and 80% 
respectively. When these values were incorporated into 
the above equation, nSe = 49 samples and nSp = 205 sam-
ples. A sufficient sample size of 238 DBS was analysed.
Data analysis
For DBS samples, the concentration of HRP2 extracted 
was determined via standard curves. For the standard 
D6 parasite culture, 1 parasite/µL =  1.7  pM HRP2 (see 
Additional file 1: Figure S1). All error bars shown in the 
data represent the standard deviation between replicates 
of the samples analysed. Intra-assay variability was calcu-
lated by finding the standard deviation of replicates run 
at a single concentration, in a single assay, and dividing 
by the mean of the replicates. Inter-assay variability was 
found by determining the standard deviation of a single 
concentration for assays run on different days and divid-
ing by the mean value for that concentration. The sen-
sitivity and specificity of the DBS HRP2 ELISA method 
was determined through a ROC curve analysis using 
microscopy results as the gold standard.
Results
Optimization of extraction parameters
In order to analyse HRP2 in a DBS sample, the extrac-
tion method had to be optimized. The technique used 
for mixing was chosen by extraction into PBST using 
rotisserie, vortex, and sonicator mixing as well as with-
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as the energy imparted by the mixing method increased 
(Fig.  1a). Vortex mixing was selected as it resulted in a 
high recovery and is also feasible in low resource settings 
[18]. No difference in recovery was seen between 10 and 
30 min of mixing (see Additional file 1: Figure S2).
Extraction buffer compositions with varying salt con-
centrations and lysis reagents were also explored. The 
composition of the buffers analysed are listed in Addi-
tional file 1: Table S1. A greater percent recovery of HRP2 
was observed with buffers which contained nonionic sur-
factants, likely due to greater solubilization of the protein 
by the long polyethylene glycol chains. Salt concentration 
did not affect recovery (Fig. 1b). PBST (Buffer 1) was cho-
sen as the extraction buffer.
The ratio of extraction buffer to 6  mm DBS was also 
examined for impact on HRP2 recovery. Our study 
showed no significant difference in recovery for volumes 
of 150–250 µL per 6 mm DBS (see Additional file 1: Fig-
ure S3). Similarly it was found that extracting two, 6 mm 
DBS in 300  µL of buffer compared to one, 6  mm DBS 
doubled the slope of the standard curve, increasing assay 
sensitivity (see Additional file 1: Figure S4).
Finally, the effect of heating was analysed by placing 
DBS in extraction buffer and then in a heat block at 40, 60 
and 80 °C for 10 min. The samples were then vortexed for 
10 min before analysis by ELISA. Heating at 60 °C increased 
recovery of HRP2 from approximately 70% to 90% (Fig. 1c). 
For this method, room temperature was chosen to reduce 
necessary instrumentation, but a heating step can be added 
if increased assay sensitivity is required.
Dried blood spot card type and Plasmodium falciparum 
histidine‑rich protein 2 recovery and stability
903 cards are designed for DBS collection while W3 is 
made for filtration. Because 903 cards are more expen-
sive than W3, many field studies with limited budgets 
have employed W3. To determine if the paper type has an 
effect on HRP2 recovery, DBS samples were prepared on 
each card type. It was found that recovery of HRP2 from 
903 cards was consistently 20% greater than recovery 
from samples on W3 (Fig.  1d). HRP2 stability was also 
assessed with both card types. It was observed that HRP2 
was less stable in W3 samples with only 30% of the ini-
tial HRP2 recovery observed after being stored at room 
Fig. 1 Optimization of parameters for the extraction of Plasmodium falciparum histidine-rich protein 2 (HRP2) from dried blood spot (DBS) samples. 
a Mixing method, b extraction buffer, c temperature and d dried blood spot card type
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temperature for 6 months. Samples on 903 cards retained 
50% of the initial recovery after being stored for 6 months 
at room temperature. Additionally, samples on 903 cards 
retained 100% of the original recovery after storage for 
6 months at −20 and −80 °C (Fig. 2).
Comparison to traditional Plasmodium falciparum 
histidine‑rich protein 2 ELISA
Using the optimized protocol for extraction of two, 
6  mm DBS in 300  µL of PBST, with vortex mixing for 
10  min, standard curves were generated from parasite-
spiked DBS samples on 903 cards. The resulting curves 
were highly reproducible with an intra-assay variability 
of 7% and inter-assay variability of 10% (n = 3) (Fig. 3). 
The limit of detection (LOD), defined as 3σblank/slope, 
was 4 ± 5 parasites/µL (8 ± 8 pM HRP2). Samples were 
then analysed simultaneously on the previously reported 
HRP2 ELISA and the DBS HRP2 ELISA [13]. Upon anal-
ysis with a paired t test, all p values were greater than 
0.05 proving there was no statistical difference between 
the HRP2 levels found by the two methods (Fig. 3).
Analysis of patient samples from rural Zambia
The standard curves used for analysis of DBS patient 
samples were made from parasite-spiked diluted whole 
blood. These assays, performed at Macha Research Trust, 
had an intra-assay variability of 6% and an inter-assay var-
iability of 18% (n = 14). The LOD determined by 3σblank/
slope was 0.165 ± 0.003 pM HRP2 (see Additional file 1: 
Figure S5). 238 DBS patient samples collected within 24 h 
Fig. 2 The stability of Plasmodium falciparum histidine-rich protein 2 (HRP2) in dried blood spots, over time, in different storage conditions. Stability 
on 903 Protein Saver cards (left) and Whatman 3 filter paper (right)
Fig. 3 The reproducibility and accuracy of the developed dried blood spot (DBS) Plasmodium falciparum histidine-rich protein 2 (HRP2) ELISA. DBS 
standard curves run on three different days (left) and comparison of HRP2 values between the DBS ELISA and a traditional ELISA (right)
Page 6 of 10Gibson et al. Malar J  (2017) 16:350 
or at least 28 days after malaria diagnosis and treatment 
were analysed by DBS HRP2 ELISA (see Additional file 1: 
Table S2). Using microscopy as the gold standard, a ROC 
curve was used to determine the sensitivity and specific-
ity of the assay. It was found to have sensitivity of 94% (CI 
89–97%) and specificity of 89% (CI 79–95%) when the 
threshold was set at 3.5 pM HRP2 (Fig. 4). The area under 
the ROC curve was 0.96, indicating excellent accuracy of 
the method. Furthermore, using this threshold, the posi-
tive predictive value (PPV) for the assay was 95% and the 
negative predictive value (NPV) was 86%.
Plasmodium falciparum histidine‑rich protein 2 clearance
For 10 patients, all 15 time points were analysed and used 
to study the clearance of parasite and HRP2 after treat-
ment (Fig.  5; Additional file  1: Figure S6). For these ten 
patients, the median clearance time of the parasite was 
1.38  days (0.5–3  days). For HRP2, two patients were 
HRP2 negative by the ELISA at all time points, so they 
were excluded from the median calculation. The median 
clearance time of HRP2 for the remaining eight patients 
was 5  days (0.25–21  days). Various HRP2 clearance 
trends were observed when looking at each patient indi-
vidually. As mentioned previously, two patients with low 
initial parasitaemias (see Additional file 1: Figure S6C, F), 
were negative for HRP2 according to the 3.5 pM thresh-
old. Patient 51 (see Additional file 1: Figure S6E) had rela-
tively low HRP2 levels before a large spike at t = 1 day. 
Patients 25, 27 and 45 (Fig.  5a; Additional file  1: Figure 
S6A, B, respectively) all showed HRP2 levels which cor-
responded with parasite load but with a lag in clearance 
time. Patients 49 (see Additional file 1: Figure S6D) and 
50 (Fig. 5b) displayed the same trend except for a couple 
of spikes corresponding to a decrease in parasite levels. 
The HRP2 level in Patient 43 (Fig.  5c) spiked and fell 
throughout the study but was cleared by the last time 
point. Finally, Patient 44 (Fig.  5d) showed decreasing 
HRP2 levels over time until they began to rise at the last 
three time points while parasite levels remained negative.
To ascertain whether there was a correlation between 
parasite and HRP2 levels, the DBS HRP2 ELISA results 
for all 328 patient samples were compared to microscopy. 
A positive, linear association was observed, with a Spear-
man correlation coefficient (ρ) equal to 0.70 (95% CI 
0.63–0.75, p < 0.0001) (Fig. 6).
Discussion
Plasmodium falciparum histidine‑rich protein 2 and dried 
blood spots
Extraction of HRP2 from DBS was achieved reproduc-
ibly, but several factors affected its efficiency, including 
the type of paper on which the DBS was prepared. This is 
an important variable to consider, as 903 cards cost up to 
eight times more than W3. As shown in the results sec-
tion, 903 cards had up to a 20% greater recovery of HRP2, 
and HRP2 did not degrade in these cards when stored 
frozen for 6  months (Figs.  1d, 2). These results indicate 
that although the more cost effective alternative is often 
chosen in field study design, in this case the additional 
cost enhances performance. The authors conclude that 
903 cards most likely provide a more stable matrix for 
protein storage, and their increased thickness allows for 
a greater volume of blood in a specific DBS area resulting 
in greater protein recovery.
ROC curve analysis
ROC curves are used as a metric to determine the sen-
sitivity and specificity of a diagnostic assay as compared 
to the chosen gold standard. An ideal ROC curve forms 
a 90º angle in the left corner of the graph, which corre-
sponds to a test with 100% sensitivity and 100% speci-
ficity. In this analysis, the DBS HRP2 ELISA was found 
to have a sensitivity of 94% and a specificity of 89% with 
a threshold of 3.5  pM HRP2 (Fig.  4). This result dem-
onstrates the developed DBS HRP2 ELISA is a reliable 
diagnostic for malaria. Reduced specificity compared 
to sensitivity can be attributed to the fact that the gold 
standard for malaria diagnosis (microscopy) detects 
the malaria parasite rather than the protein biomarker 
detected with the DBS HRP2 ELISA. This discrepancy 
can result in false positives by DBS ELISA, because HRP2 
can persist in the blood stream days to weeks after par-
asite clearance [19, 20]. Furthermore, microscopy has 
shortcomings of its own, including a lack of sensitivity. 
In general, ELISA is more sensitive than microscopy [21]. 
Fig. 4 ROC curve for dried blood spot (DBS) Plasmodium falciparum 
histidine-rich protein 2 (HRP2) ELISA when compared to clinical 
microscopy values for patient samples from rural Zambia. Sensitiv-
ity of the assay was 94% (CI 89–97%) and specificity was 89% (CI 
79–95%) when the threshold was set at 3.5 pM HRP2
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As a result, false positives could result from the ability of 
the DBS HRP2 ELISA to detect malaria infections that 
are not seen by microscopy.
While a lower threshold would allow for detection of 
more truly HRP2-positive samples, it would also result 
in detection of residual HRP2 that is not the result of an 
active malaria infection. This observation points to a dis-
advantage of HRP2 as a biomarker, as its persistence can 
result in misdiagnosis of patients and improper treatment 
[22]. To address this issue, an alternative protein bio-
marker that quickly clears from the bloodstream, Plas-
modium lactate dehydrogenase (pLDH), is being further 
explored in our lab [20, 23]. Nonetheless, the importance 
of detection of HRP2 remains, as it continues to be the 
most sensitive and prevalently used protein biomarker 
for detection of falciparum malaria infections [12].
Biomarker clearance
Several different trends were observed in the clearance 
patterns of HRP2, indicating that the response of each 
patient to the disease is different. Despite this, some 
similarities were observed, including delayed HRP2 
clearance compared to parasite clearance, a result of the 
persistence of HRP2 [24]. Additionally, the spikes seen in 
several patients directly after a decrease in parasite load 
are likely caused by the release of HRP2 upon parasite 
death [25]. Finally, in one patient, HRP2 levels increased 
in the final time points indicating reinfection or recrudes-
cence may have occurred (Fig.  5d). Reinfection is when 
an individual is successfully treated for malaria but then 
becomes sick again with an entirely new malaria infec-
tion [26]. Recrudescence occurs when the same malaria 
infection is never fully eliminated by treatment and reap-
pears [27]. Without sample genotyping the cause of the 
HRP2 spike in this sample cannot be confirmed [28, 29].
Using the ROC curve threshold, information can be 
gathered about infection levels and HRP2 persistence 
in the blood. For this study, infections levels were clas-
sified as follows: low (0–14,999 parasites/µL), medium 
(15,000–75,000 parasites/µL) and high (≥75,000 para-
sites/µL). Besides the case discussed above, Patients 3 
and 37 (see Additional file 1: Table S2) had HRP2 levels 
that were positive at the end of the time study mean-
ing these samples contained HRP2 as long as 30  days 
after the beginning of treatment. Furthermore, samples 
from Patients 43 and 45 (Fig. 5c; Additional file 1: Figure 
Fig. 5 Representative data of different Plasmodium falciparum histidine-rich protein 2 (HRP2) clearance trends that were observed in patient 
samples collected at 15 time points, over a 35-day period. The concentration of HRP2 extracted from the dried blood spot (DBS) samples and the 
parasitaemia determined by microscopy are plotted against time. a Patient 27, b Patient 50, c Patient 43 and d Patient 44
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S6B, respectively), which were analysed for the full time 
study, retained HRP2 past the median time-to-clear-
ance of 5 days. It could be expected that these extended 
clearance times were a result of high level infections 
but instead it was found that the initial parasite level 
for each of these patients was below 25,000 parasites/
µL. This result suggests that persistence of HRP2 was a 
result of chronic infections. In chronic infections, low-
level parasitaemias can persist in a patient for years, 
with minimal symptoms, and then become sympto-
matic [30–32]. The longevity of the infection can allow 
for build-up of HRP2 over time, so even though the par-
asite load is low, a significant amount of HRP2 persists 
in the blood.
Association between parasite and biomarker levels
A correlation between parasite and HRP2 levels meas-
ured by microscopy and DBS HRP2 ELISA respectively 
was observed (Fig.  6). The Spearman correlation coef-
ficient (ρ) was 0.70, and this result statistically proves 
an association between these two variables. The 
strength of the association is considered to be moder-
ate (ρ =  0.5–0.7) to high (ρ =  0.7–0.9) [33]. As can be 
seen in Additional file  1: Figure S1, in the case of para-
site culture this correlation between HRP2 and parasite 
levels is direct. Several different factors could have con-
tributed to the decrease in the strength of association 
observed with patient samples. For example, the lack of 
strictly controlled storage conditions for the DBS sam-
ples likely caused protein degradation and variability 
in extraction efficiency. As a result, in the analysis of 
the patient samples there were other influences on pro-
tein recovery besides the initial parasitaemia of the 
sample. Additionally, the amount of HRP2 produced by 
the parasite is dependent on the life stage and strain [25, 
34]. Patient samples have much greater variety in these 
parameters than parasite culture, resulting in a weaker 
association between HRP2 and parasite levels. Other lit-
erature reports have seen similar discrepancies in patient 
samples, as some report correlation between HRP2 levels 
and disease severity, while others do not [35, 36]. None-
theless, in this work a positive association between HRP2 
and parasite levels was observed, indicating the useful-
ness of the HRP2 biomarker in malaria diagnosis.
Conclusions
Dried blood spots represent a common and simple 
sample collection method for clinical and non-clinical 
settings. Samples stored in this way are stable and eas-
ily shipped. In order to analyse these samples, methods 
must be optimized for extraction of a specific biomarker 
and subsequent analysis. This is a report of a highly 
reproducible procedure for extraction of the malarial bio-
marker HRP2 and subsequent analysis of the protein by 
ELISA. This assay was then used to analyse patient sam-
ples in rural Zambia and was found to have a 94% sensi-
tivity and 89% specificity. Examination of patient samples 
also revealed trends in biomarker clearance, showing 
sustained HRP2 in the blood. Furthermore, a positive, 
linear association between parasite and HRP2 levels was 
observed. Thus, the reported method is reliable for detec-
tion of malaria from commonly collected dried blood 
spot samples and can be applied further in epidemiologi-
cal studies and to assist in the development of improved 
diagnostics through increased understanding of disease 
characteristics.
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